• ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) (age 40 and under)
  • S1701  A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma